Pan-cancer analysis and experimental verification of cytochrome B561 as a prognostic and therapeutic biomarker in breast cancer
CYB561 exhibits aberrant expression in tumors, particularly in BRCA, and serves as a predictive marker for immune-related therapies and a prognostic indicator in BRCA.
Authors
- Xinghui Sun (ORCID: https://orcid.org/0000-0002-1156-0375)
- Zhijian Huang (ORCID: https://orcid.org/0000-0003-1601-3802)
- Peizhang Liu
- Hongxiang Lin
- Yuanyuan Han (ORCID: https://orcid.org/0000-0002-8843-6073)
- Xiaoting Qiu
- Guanglong Dong (ORCID: https://orcid.org/0000-0002-2670-0609)
- Zihuan Peng
Institutions
- Northeastern University (US)
- Fujian Medical University (CN)
- Massachusetts College of Pharmacy and Health Sciences (US)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1007/s12672-025-02094-1
- Citations
- 1
- Primary Topic
- Bioinformatics and Genomic Networks
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Beijing Xisike Clinical Oncology Research Foundation